Physician profile
Elaine C Wirrell
NPI 1255526430
$159,697.54
in general payments reported to CMS, 2019-2025
22 companies · $55K in 2025
The $55K reported for 2025 was more than what 98% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $11K · 2021: $17K · 2022: $12K · 2023: $19K · 2024: $26K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $84K · Travel and Lodging: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Food and Beverage: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $84,355.31 |
| Travel and Lodging | $11,944.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Food and Beverage | $1,010.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocodex, INC. | $40,237.08 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $23,000.00 | 2019-2025 | Acp-101 |
| Ucb Sa | $17,028.58 | 2023-2025 | Fintepla, Vimpat |
| Jazz Pharmaceuticals INC. | $16,013.35 | 2023-2025 | Epidiolex |
| Biomarin Pharmaceutical INC. | $12,468.72 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $10,525.00 | 2023-2025 | |
| Ucb, INC. | $9,433.64 | 2022-2025 | Fintepla |
| Takeda Pharmaceuticals U.S.A., INC. | $6,175.00 | 2023 | |
| Amicus Therapeutics, INC. | $4,400.00 | 2019-2021 | |
| Greenwich Biosciences, INC. | $4,320.00 | 2020 | |
| Mallinckrodt Enterprises LLC | $4,271.17 | 2019 | |
| Eisai INC. | $3,240.00 | 2022 | |
| Eisai Co., Ltd. | $2,400.00 | 2021 | |
| Zogenix INC. | $2,400.00 | 2020-2021 | |
| Immedica Pharma US, INC. | $1,515.00 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $1,020.00 | 2021 | |
| Hikma Pharmaceuticals USA | $1,000.00 | 2024 | |
| Cipla USA INC. | $250.00 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Wirrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.